Hepion Pharmaceuticals Inc (NASDAQ:HEPA)

2.30
Delayed Data
As of Jan 15
 -0.04 / -1.71%
Today’s Change
1.00
Today|||52-Week Range
6.90
+5.02%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$73.7M

Company Description

Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

Contact Information

Hepion Pharmaceuticals, Inc.
399 Thornall Street
Edison New Jersey 08837
P:(732) 902-4000
Investor Relations:
(646) 274-3580

Employees

Shareholders

Other institutional12.27%
Individual stakeholders0.22%
Mutual fund holders0.14%

Top Executives

Robert T. FosterPresident, Chief Executive Officer & Director
John T. CavanChief Financial & Accounting Officer
Daren UreChief Scientific Officer
Patrick MayoSenior Vice President-Clinical Pharmacology
Daniel TrepanierSenior Vice President-Drug Development